A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

Background: Inhaled antibiotics are standard of care for persons with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infection. APT-1026 (levofloxacin inhalation solution, LIS) is fluoroquinolone in development. We compared the safety and efficacy of LIS to tobramycin inhalation so...

Full description

Bibliographic Details
Main Authors: Elborn, J. Stuart, Geller, David E., Conrad, Douglas, Aaron, Shawn D., Smyth, Alan R., Fischer, Rainald, Kerem, Eitan, Bell, Scott C., Loutit, Jeffery S., Dudley, Michael N., Morgan, Elizabeth E., VanDevanter, Donald R., Flume, Patrick
Format: Article
Published: Elsevier 2015
Subjects:
cystic fibrosis
antibiotics
Pseudomonas
aerosol
fluoroquinolone
Online Access:https://eprints.nottingham.ac.uk/31682/

Similar Items

Similar Items